Clinical trial
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small…
NCT00290407 · University of Louisville, Other · Terminated
Key facts
| NCT number | NCT00290407 |
|---|---|
| Title | Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) |
| Official title | Phase II Study of Rituximab Plus B-Glucan in Patients With Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) |
| Lead sponsor | University of Louisville, Other |
| Collaborators | James Graham Brown Cancer Center |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Chronic, Lymphoma, Small Lymphocytic |
| Intervention type | Dietary Supplement, Drug |
| Interventions | Rituximab, Beta-Glucan |
| Enrollment | 2 |
| Start date | Mar 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Feb 13, 2006 |
| Last update posted | May 4, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: